The Therapeutic Goods Administration (TGA) received 6,232 spontaneous reports of AEFI for vaccines administered in Australia during 2024. Investigators reported an annual reporting rate of 22.9 per 100,000 population and 25.7 per 100,000 vaccine doses. Those figures represent a modest rise compared with 2023, when the rates were 20.8 per 100,000 population and 24.1 per 100,000 doses. Analysts attributed the increase primarily to a change in zoster vaccination policy and product choice, rather than a new safety pattern detected across all vaccines.
The report frames an adverse event following immunisation as any untoward medical occurrence after vaccination that is not necessarily causally linked to the vaccine. Analyses of spontaneous reports are performed on an ongoing basis and also compiled annually to detect new safety concerns or shifts in known safety issues. The abstract did not provide granular methodological details such as the specific case review algorithm, time windows for event attribution, or stratified denominators by individual vaccine brands beyond the population- and dose-based rates provided in the summary.
The authors noted that the introduction of a new recombinant zoster vaccine (RZV, Shingrix) onto the National Immunisation Program from November 2023, together with an expanded eligible population for zoster vaccination, likely drove the observed rise in reporting rates for 2024. In the dataset, Shingrix was associated with the highest number of reported AEFIs for the year.
For vaccines introduced or updated in 2024, the report broke down common event types by product. The COVID-19 XBB.1.5 formulations (Comirnaty XBB.1.5 and Spikevax XBB.1.5) were most often associated with reports of medication errors and nonspecific gastrointestinal symptoms. The DTPa-HepB-IPV-Hib combination vaccine (Vaxelis) most commonly drew reports of hypersensitivity and pyrexia, the investigators observed. Reports related to the adjuvanted recombinant RSV pre-fusion F protein vaccine (Arexvy) most frequently involved medication errors and exposure during pregnancy. The abstract did not include counts by vaccine batch, nor did it present stratified risk estimates adjusted for age or dose number.
Across the national dataset, the five most frequently reported categories were medication errors; hypersensitivity; gastrointestinal nonspecific symptoms; pyrexia; and injection site reaction. Medication errors appeared repeatedly in reports for several vaccines, suggesting system or administration factors contributed substantially to the overall reporting profile. The authors did not provide detailed breakdowns of the medication-error subtypes in the abstract, so the specific nature—wrong dose, incorrect schedule, or administration technique—was not described in the source text.
Hypersensitivity and pyrexia were recurrent across multiple products, a pattern consistent with expected reactogenicity profiles for many licensed vaccines. Nonspecific gastrointestinal symptoms and injection site reactions were also commonly reported, and the report lists these categories without assigning causality. Data indicated that newly used or reformulated vaccines tended to generate more reports of common adverse events and administration errors during their initial rollout phase.
Fewer deaths were reported after vaccination in 2024 than in 2023: 28 reports versus 34, respectively. The authors stated that none of the 28 deaths reported in 2024 indicated an emerging safety signal. The abstract did not detail the processes used to investigate each death, nor did it list contributing causes or the temporal relationship between vaccination and death for individual reports. The absence of an emerging signal indicates that, in aggregate review, investigators did not detect a pattern suggestive of vaccine-attributable mortality within the reviewed reports.
The report draws on spontaneous surveillance reported to the TGA; the authors emphasise that routine analyses are designed to detect new safety issues or changes in known issues through both continuous review and annual compilation. Spontaneous reporting systems are valuable for early detection but have inherent limitations: underreporting, variable report quality, and limited ability to establish causality. The abstract did not specify whether complementary data sources (for example, active surveillance platforms, electronic health records, or linkage to mortality data) were used in parallel for signal validation within this summary.
The dataset documented product-specific patterns after program changes—most notably the shift to RZV (Shingrix) on the National Immunisation Program and the introduction of XBB.1.5 COVID-19 vaccine formulations—but the source did not report detailed denominators by brand, time-to-event windows, or analytical methods used for signal detection. Those methodological gaps limit interpretation of relative event rates and preclude quantitative risk comparison across brands from the abstract alone.
Limitations explicitly noted by the authors in the abstract include the nature of spontaneous reports and the absence of a detected emerging safety signal among the 28 deaths in 2024. The report ends with routine surveillance continuing; the abstract did not list specific next regulatory steps, planned in-depth product investigations, or timelines for subsequent detailed analyses.